Statements (34)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiprotozoal drug
phospholipid derivative |
| gptkbp:approvalYear |
2002
|
| gptkbp:approvedBy |
gptkb:India
|
| gptkbp:ATCCode |
P01CX05
|
| gptkbp:brand |
gptkb:Impavido
gptkb:Miltefos |
| gptkbp:CASNumber |
58066-85-6
|
| gptkbp:chemicalFormula |
C21H46NO4P
|
| gptkbp:contraindication |
pregnancy
|
| gptkbp:discoveredBy |
gptkb:Asta_Medica
|
| gptkbp:hasSMILES |
CCCCCCCCCCCCCCCCP(=O)(OCC[N+](C)(C)C)O
|
| https://www.w3.org/2000/01/rdf-schema#label |
miltefosine
|
| gptkbp:KEGGID |
gptkb:D02141
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
disrupts cell membrane of protozoa
|
| gptkbp:meltingPoint |
86-88°C
|
| gptkbp:molecularWeight |
407.6 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201217
gptkb:DB09031 3599 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea abdominal pain teratogenicity |
| gptkbp:UNII |
1LQA4OC4SY
|
| gptkbp:usedFor |
gptkb:visceral_leishmaniasis
leishmaniasis amoebic meningoencephalitis |
| gptkbp:bfsParent |
gptkb:Leishmania_donovani
gptkb:Leishmaniasis |
| gptkbp:bfsLayer |
5
|